Revelation Biosciences, Inc. · NASDAQ:REVB
Revelation Biosciences — Petra Acquisition — SPAC Merger (August 2021)
39 slides from Revelation Biosciences's SPAC merger presentation, Aug 31, 2021
Slide 1: Corporate Presentation / August 2021
Using cutting edge science to develop innovative therapeutics and diagnostics Corporate Presentation / August 2021
Slide 2: Legal Disclaimer
Legal Disclaimer About this Presentation This presentation is provided for informational purposes only and is subject to change . The information contained herein does not purport to be all - inclusive . The data contained herein is derived from various internal and external sources, and may rely up
Slide 3: Forward-Looking Statements
Forward - Looking Statements Certain statements made herein are "forward - looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements may be identified by the use of words such as "anticipate", "believ
Slide 4: Respiratory Viral Infections: A Perpetual Problem
Respiratory Viral Infections: A Perpetual Problem • COVID - 19 exposed gaps in currently approved methods to diagnose, prevent and treat respiratory viral infections • Existing and emerging respiratory viruses effect large numbers of people annually and have a substantial social and economic impact.
Slide 5: Revelation Biosciences – Our Focus
Revelation Biosciences – Our Focus 5 • The innate immune response is our first line of defense against viral invasion • The innate response is non - specific and is immediately activated upon viral invasion • It works via the production and activity of cytokines and chemokines that inhibit the abili
Slide 6: Revelation Biosciences – Executive Summary
Revelation Biosciences – Executive Summary 6 Revelation’s portfolio consists of three product candidates: REVTx - 99 (Phase 2), REVTx - 200 (Preclinical) and REVDx - 501 (Pre - 510(k)) REVTx - 99 is a broad anti - viral nasal drop solution in development for the prevention or treatment of respirator
Slide 7: Development Pipeline
Development Pipeline 7 Pipeline consists of two therapeutic product candidates (REVTx - 99 and REVTx - 200) and one diagnostic product (REVDx - 501) Therapeutic Pipeline Discovery Preclinical Phase 1 Phase 2 Phase 3 Approval REVTx - 99 REVTx - 200 Diagnostic Pipeline Research Development Clinical Te
Slide 8: Project Milestones
Project Milestones Project Milestone Estimated Timing REVTx - 99: Nasal drops for the prevention and/or treatment of respiratory viral infection • Completion of Phase 1 single dose escalation x Jan 2021 • Completion of Phase 1 multidose cohort x Mar 2021 • Phase 1 clinical Proof - of - Principle dat
Slide 9: REVTx-99 - For the Prevention of Respiratory Viral Infection
REVTx - 99 For the Prevention of Respiratory Viral Infection
Slide 10: REVTx-99 Overview
REVTx - 99 Overview • REVTx - 99 is prophylaxis for respiratory viral infections ▪ Active ingredient: Phosphorylated Hexa - Acyl Disaccharide ( PHAD) ▪ Formulation: intranasal drops • Mechanism of action: REVTx - 99 stimulate s the innate immune system via TLR4 TRIF pathway agonism to produce protec
Slide 11: Strong Scientific Rationale
Strong Scientific Rationale 4 Emerging Microbes and Infections, Dec 11, 2019 DOI: 10.1080/22221751.2019.1698271 5 Journal of Biological Chemistry, June 25, 2020 DOI: 10.1074/jbc.AC120.013788 6 Vaccine, April 2010, DOI:10.1016/j.vaccine.2010.03.062 7 Bio. Pharmacology Vol. 183, Jan. 2021, 114316 DOI:
Slide 12: PHAD is effective against viral infections via innate immune activation
PHAD is effective against viral infections due to the activation of innate immune system cytokines such as interferon Preclinical Activity of PHAD in Mouse Model 1 Trends in Microbiology, October 1, 2002, DOI: 10.1016/S0966 - 842X(02)02426 - 5 12 0 10 20 30 40 50 60 70 80 90 100 -3 -2 -1 0 1 2 3 4 5
Slide 13: RVL-HV01: Phase 1 Healthy Volunteer Study
• Total number of subjects: 48 (6 cohorts, 8 subjects per cohort) • Cohorts 1 - 5: treated group (N=6) receives a dose of either 5, 15, 30, 50 or 100 µg • Cohort 6: treated group (N=6) receives a dose of 100 µg daily x 5 • Readouts : Safety measurements, systemic and nasal cytokine levels, systemic
Slide 14: Summary of Phase 1 Study Results
Summary of Phase 1 Study Results Safety • All doses of REVTx - 99 were well tolerated with no significant or serious adverse events • Drug related adverse events were all mild and limited to the local nasal mucosa and included runny nose or mild nasal congest ion at the higher doses Biomarkers • REV
Slide 15: IP-10 as key cytokine of interest
1 PLoS ONE, 2011 DOI:10.1371/journal.pone.0016333 2 PREP - 001 is a TLR - 3 agonist that demonstrated effectiveness in preventing both infection with rhinovirus and influenza in human clinical studies. The primary cytokine upregulated by PREP101 is IP - 10. IP - 10 was identified a priori as the key
Slide 16: REVTx-99 Produced a Dose Dependent Increase in Intranasal IP-10
Placebo N: 88 Mean: 1.5 50 ug N: 48 Mean: 9.1 P: 0.06 100 ug N: 48 Mean: 16.7 P: 0.10 50+100 N: 96 Mean: 12.9 P: 0.03 50+100+multi N: 120 Mean: 10.9 P: 0.02 5+15+30 N: 144 Mean: 1.5 P: 0.9 Fold change from Baseline REVTx - 99 Produced a Dose Dependent Increase in Intranasal IP - 10 16 x REVTx - 99 s
Slide 17: REVTx-99 also Stimulated other Protective Cytokines
REVTx - 99 also Stimulated other Protective Cytokines MCP - 1 and IFN - ࢽ tracked with IP - 10 0 20 40 60 80 100 120 0 200 400 600 800 1000 1200 0 50 100 150 200 MCP - 1, IFN - g (pg/mL) IP10 (pg/mL) Time (hours) IP10-Right MCP1-Right IFN-g-Right 50 µg N: 11 Rate: 27% P: 0.05 0% 5% 10% 15% 20% 25% 3
Slide 18: Next Step: Phase 2 Viral Challenge Study
• Objective: To evaluate the efficacy of REVTx - 99 in reducing influenza virus load in the upper airways during infection • Primary Endpoint: Are a under the curve (AUC) of viral load by qPCR from nasal pharyngeal swabs • REVTx - 99 • REVDx - 200 • REVDx - 501 Next Step: Phase 2 Viral Challenge Stu
Slide 19: REVTx-99 has Multiple Possible Uses with Potentially Large Markets
• REVTx - 99 • REVDx - 200 • REVDx - 501 Market Need: REVTx - 99 has Multiple Possible Uses with Potentially Large Markets 19 Seasonal virus prophylaxis (e.g. influenza season ) Seasonal Prophylaxis Potential Target Population At Risk Population. For example: • Health care workers • Elderly • Immuno
Slide 20: REVTx-99 - For the Treatment of Chronic Nasal Congestion
REVTx - 99 For the Treatment of Chronic Nasal Congestion
Slide 21: Rationale for Chronic Nasal Congestion: Eotaxin, Allergies and REVTx-99
Rationale for Chronic Nasal Congestion: Eotaxin, Allergies and REVTx - 99 21 • Eotaxin propagates allergies and inflammation • Eotaxin binds to its receptor CCR3, which is expressed on a range of different cell types • A number of effector cells associated with allergies express the CCR3 receptor 1.
Slide 22: Phase 1b Nasal Challenge Study (RVL-CLR01)
Phase 1b Nasal Challenge Study (RVL - CLR01) 22 Confidential Study Title: Effect of REVTx - 99 on Nasal Challenge with Allergen in Participants with Chronic Rhinosinusitis without Polyps Milestones • Enrollment up to 28 participants, randomized 1:1 across 4 cohorts • This will be a Phase 1b, randomi
Slide 23: REVTx-200 - Intranasal PHAD for Improved IM Vaccination
REVTx - 200 Intranasal PHAD ® for Improved Intramuscular (IM) Vaccination
Slide 24: REVTx-200 Overview
REVTx - 200 Overview • REVTx - 200 is being developed as an intranasal adjunct to intramuscular vaccines to produce a superior, more complete immunization • REVTx - 200 is based on the same platform as REVTx - 99 • IP on formulation and method have been filed • Development rationale ▪ IM vaccination
Slide 25: REVDx - Rapid testing kit for viral infection
REVDx - 501 Rapid testing kit for viral infection
Slide 26: REVDx-501: Broadly Applicable to Most Infectious Viruses
REVDx - 501: Broadly Applicable to Most Infectious Viruses • REVDx - 501 (REVID Œ ) is a diagnostic device in development for the detection of respiratory viral infection (SARS - CoV - 2, influenza A and B, parainfluenza, etc.) • REVDx - 501 detects IP - 10, a key cytokine that is upregulated in nas
Slide 27: A Universal Screening Tool
A Universal Screening Tool Current Testing Paradigm • REVID Rapid Screen allows for testing of large bodies of people because test: ▪ Works regardless of virus type and any viral variants ▪ Is rapid ▪ Is inexpensive REVID Œ Rapid Screen REVID Rapid Screen will allow large numbers of people to be scr
Slide 28: REVDx Market Need: Multiple Possible Uses
Market Need: REVDx - 501 has Multiple Possible Uses with Potentially Large Markets 28 The simplicity of the kit will allow individuals to make informed decisions on their general health and whether to quarantine or go about daily life Individual Screening Tool Potential Target Population General pop
Slide 29: Excellent Correlation between REVID and PCR for COVID
Excellent Correlation between REVID Œ and PCR for COVID COVID PCR Positive (N=37) COVID PCR Negative (N=153) REVID Positive 37 21 REVID Negative 0 132 • The results from the REVID Test Kit are in good agreement with PCR ▪ 0% false negative rate for replicating SARS - CoV - 2 virus ▪ 14% false positi
Slide 30: Management Leadership and Board of Directors
Management Leadership and Board of Directors
Slide 31: Board – R&D Leadership, Development, Commercialization, Finance
Board – R&D Leadership, Therapeutic & Diagnostic Development, Commercialization, Finance and Transactional Success George Tidmarsh M.D., Ph.D. Chairman M.D. and Ph.D. from Stanford University. Currently Adjunct Faculty of Pediatrics and Neonatology. Over 30 years of experience in biotechnology, incl
Slide 32: Management has a Strong History Building Successful Commercial Organizations
Management has a Strong History Building Successful Commercial Organizations (e.g., 3 NASDAQ and 1 NYSE Listings) James Rolke Director and Chief Executive Officer Over 30 years of experience in the biotechnology industry. Chief Scientific Officer of La Jolla Pharmaceutical Company, development of mu
Slide 33: Key Takeaways
Key Takeaways 33 Revelation Portfolio Scientific Rationale Near Term Value Drivers Experienced Management and Scientific Team
Slide 34: Transaction Overview
BilOrsiGiiEIN CES: 2 REVELATION Transaction Overvie
Slide 35: Revelation Biosciences to go public through a SPAC merger with Petra Acquisition
Revelation Biosciences, Inc. to go public through a SPAC merger with Petra Acquisition, Inc. (PAIC) 35 • PAIC is a healthcare - focused Special Purpose Acquisition Company (“SPAC”) that raised approximately $74 million in its IPO in Oc tober 2020, with its common stock trading on NASDAQ under the sy
Slide 36: Sources and Uses
36 Sources and Uses Sources Amount ($M) Cash From PAIC Trust (1) $73.5 Revelation Equity Rollover $105.0 PAIC Sponsor Equity $18.4 Total Sources $196.9 Uses Amount ($M) Revelation Equity Rollover $105.0 PAIC Sponsor Equity $18.4 Net Cash to Revelation BS (1)* $65.0 Assumed Transaction Expenses (2) $
Slide 37: Beneficial Holders
Beneficial Holders — 2 REVELATION Blo SGIiEN GES
Slide 38: Revelation Beneficial Holders
Revelation Beneficial Holders Significant Beneficial holders Percent pre - merger 1 Dr. George Tidmarsh (Chairman) 17.5% Company Management 30.7% AXA IM Prime Impact Fund 2 16.5% LifeSci Venture Partners 9.4% Monashee Investments 7.9% Total 64.5% 1. Fully diluted basis 2. Series A preferred stock as
Slide 39: Thank you!
REVELATION BIOSCIENCES Thank you!